BEIJING (Reuters) - AstraZeneca Plc (AZN.L), Europe's third-biggest drug maker, will spend $100 million on research and development in China over the next three years, with a focus on cancer, a major killer in China. "China is an extremely large pharmaceutical market that is growing very rapidly," David Brennan, the company's chief executive, told reporters on Friday.
